US EditionIpsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline - Ipsen (OTC:IPSEY)
Ipsen will pay 350 million euros upfront for ImCheck, advancing ICT01 immunotherapy that doubled response rates in AML patients ineligible for intensive chemotherapy, data show.
- Ipsen will acquire all shares of ImCheck Therapeutics for 350 million euros plus up to 1 billion euros in contingent payments, CEO David Loew said the deal presents an opportunity to deliver `transformative therapies`.
- The deal centers on ICT01, targeting first-line AML patients ineligible for intensive chemotherapy, and Ipsen said it will accelerate ICT01 toward registrational studies and commercialization.
- Clinical evidence presented at ASCO indicates EVICTION trial data in 45 patients shows ICT01 in combination with Ven-Aza achieved high responses and was well tolerated.
- The transaction is expected to close by the end of Q1, subject to customary closing conditions and regulatory approvals; Centerview Partners advised ImCheck and Allen & Overy Shearman served as legal counsel to Ipsen.
- Ipsen warned that development and commercial outcomes remain uncertain, despite ICT01 receiving Orphan Drug designations from the U.S. Food and Drug Administration and European Medicines Agency.
17 Articles
17 Articles
The Phocean start-up, specializing in immuno-oncology, passes into the Ipsen giron for a minimum amount of 350 million euros, up to 1 billion. Issue: a promising treatment in development against a form of leukemia.
This acquisition involves a developing monoconal antibody in the front-line treatment of acute myeloid leukaemia in patients who cannot tolerate intensive chemotherapy.
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline - Ipsen (OTC:IPSEY)
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire all issued and outstanding shares of ImCheck Therapeutics, for which ImCheck Therapeutics' shareholde…
The Record
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment responseICT01 has the potential to be a new standard of care in combination in first line unfit…
Coverage Details
Bias Distribution
- 60% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
